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Abstract
Background: Each year in the United States an estimated 1.7 million people suffer a traumatic brain injury
(TBI). Current standard of care for these patients is seven days of phenytoin (PHT) for seizure prophylaxis.
Given the known side effect profile and drug interactions associated with the use of PHT, levetiracetam
(LEV) has been proposed as an alternative for seizure prophylaxis. This systematic review examined available
literature to determine whether or not there is sufficient evidence to recommend the use of LEV in lieu of
PHT.
Method: A highly sensitive search of Medline, CINAHL, and EBMRMultifile was conducted looking for
studies comparing the efficacy of phenytoin vs. levetiracetam in the setting of severe TBI (sTBI) using the
terms phenytoin and either levetiracetam or piracetam. In an effort to ensure that no articles that met inclusion
criteria were missed, additional searches were conducted using Google Scholar and Web of Science. A manual
search of the bibliographies of the articles to be reviewed as well as the bibliographies of background articles
was conducted.
Results: Two articles comparing LEV and PHT in the setting of sTBI were found. Neither article was able to
show a difference in the rate of seizure between patients treated with PHT and LEV. An increase in seizure
tendency on EEG for patients taking PHT was reported, as was an increase in gastrointestinal upset and
worsening of neurologic status. A modest improvement in some long term outcome measures was reported in
patients treated with LEV. Both of the studies that were found were hampered by a small n (52 and 73), which
was further limited by the studies’ methodology.
Conclusion: There is insufficient evidence to recommend the use of LEV instead of PHT for seizure
prophylaxis in the setting of sTBI. Further studies, with larger patient populations and more sound
methodology, are needed to continue to examine this issue.
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Abstract   
Background: Each year in the United States an estimated 1.7 million people suffer a 
traumatic brain injury (TBI).  Current standard of care for these patients is seven days of 
phenytoin (PHT) for seizure prophylaxis.  Given the known side effect profile and drug 
interactions associated with the use of PHT, levetiracetam (LEV) has been proposed as an 
alternative for seizure prophylaxis.  This systematic review examined available literature 
to determine whether or not there is sufficient evidence to recommend the use of LEV in 
lieu of PHT. 
Method: A highly sensitive search of Medline, CINAHL, and EBMRMultifile was 
conducted looking for studies comparing the efficacy of phenytoin vs. levetiracetam in 
the setting of severe TBI (sTBI) using the terms phenytoin and either levetiracetam or 
piracetam. In an effort to ensure that no articles that met inclusion criteria were missed, 
additional searches were conducted using Google Scholar and Web of Science.   A 
manual search of the bibliographies of the articles to be reviewed as well as the 
bibliographies of background articles was conducted. 
Results:  Two articles comparing LEV and PHT in the setting of sTBI were found.  
Neither article was able to show a difference in the rate of seizure between patients 
treated with PHT and LEV.  An increase in seizure tendency on EEG for patients taking 
PHT was reported, as was an increase in gastrointestinal upset and worsening of 
neurologic status.  A modest improvement in some long term outcome measures was 
reported in patients treated with LEV.  Both of the studies that were found were 
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hampered by a small n (52 and 73), which was further limited by the studies’ 
methodology. 
Conclusion:  There is insufficient evidence to recommend the use of LEV instead of 
PHT for seizure prophylaxis in the setting of sTBI.  Further studies, with larger patient 
populations and more sound methodology, are needed to continue to examine this issue. 
 
Keywords:  phenytoin, levetiracetam, seizure prevention, traumatic brain injury, severe 
traumatic brain injury. 
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The use of Levetiracetam and Phenytoin for Seizure Prophylaxis in the Setting of 
Severe Traumatic Brain Injury 
BACKGROUND 
Each year in the United States an estimated 1.7 million people suffer a traumatic 
brain injury (TBI).  Of those, 1.64 million are seen in the ED, 275 000 will be admitted to 
the hospital, and 52 000 patients will die. 1 Patients who suffer severe traumatic brain 
injury (sTBI) are at an increased risk of developing post-traumatic seizure (PTS), so in 
2003 the American Academy of Neurology issued a practice parameter regarding the use 
of seizure prophylaxis in the setting of sTBI.  The practice parameter recommends the 
use of phenytoin (PHT) for the prevention of early PTS, which they define as seizures 
occurring within seven days of injury.  The use of seizure prophylaxis beyond seven days 
was not recommended. 2 The practice parameter did not include a definition of “severe,” 
and research has shown that clinicians use a wide variety of criteria when deciding 
whether or not to use seizure prophylaxis in the setting of TBI.2,3 
  Seizures, including those following sTBI, are associated with an increase 
in hypoxic events, acute and sustained rises in intracranial pressure, acute blood pressure 
changes, aneurysm rupture, physical injury, and death. 3,4 There is wide agreement that 
the use of seizure prophylaxis for the first week after sTBI is beneficial, 1,2,4 the question 
now is whether PHT is still the most appropriate medication for the prevention of PTS. 
There is concern over the risk of medication interactions, as well as cutaneous 
hypersensitivity reactions associated with the use of PHT.  PHT also requires monitoring 
of serum levels and frequent dosage adjustments in order to maintain a narrow 
therapeutic window, which can increase cost as well as complexity of management. 
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 Levetiracetam (LEV) (Keppra) is a non-enzyme inducing anti-epileptic drug that 
is a possible alternative to PHT for the prevention of PTS.  In addition to a small side 
effect profile, LEV does not require serum level monitoring and, because it does not 
interact with CYP 450, there are far fewer drug interactions associated with its use.  
Importantly, LEV was approved for intravenous administration in 2006, which is critical 
for patients with sTBI who are often unable to take oral medication immediately 
following their injury. 
 Given the known issues with the use of PHT, the search for a safe, effective 
alternative for use in prevention of PTS is certainly worthwhile.  The purpose of this 
systematic review is to evaluate the existing evidence to determine whether or not LEV is 
an appropriate alternative to PHT for seizure prophylaxis in adults with sTBI. 
METHODS 
A highly sensitive search of Medline, CINAHL, and EBMRMultifile was 
conducted looking for studies comparing the efficacy of phenytoin vs. levetiracetam in 
the setting of TBI.  The databases were searched using the terms phenytoin and either 
levetiracetam or piracetam.  In an effort to ensure that no articles that met inclusion 
criteria were missed, additional searches were conducted using Google Scholar and Web 
of Science.   A manual search of the bibliographies of the articles to be reviewed as well 
as the bibliographies of background articles was conducted.  Articles meeting inclusion 
criteria were assessed for quality using the GRADE system. 
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RESULTS 
A total of two articles were found that met inclusion criteria for the review.   One 
study was a mixed prospective/retrospective cohort design (Jones et al) 5, the other was a 
prospective randomized controlled trial (Szaflarski et al). 4  Neither article reported a 
significant decrease in the number of seizures in patients treated with levetiracetam 
(LEV) when compared to phenytoin (PHT).   See Table I for characteristics of reviewed 
studies and Table II for a summary of findings. 
Jones et al 
 In a mixed prospective/retrospective design, Jones et al5 enrolled 32 consecutive 
patients with severe traumatic brain injury (sTBI).  Severe traumatic brain injury was 
defined as a post-resuscitation GCS of 3-8.  Patients prospectively enrolled were treated 
with seven days of LEV.  This cohort was compared to an historical cohort of 41 patients 
who had been treated with seven days of PHT.  Patients who exhibited clinical signs of 
seizure, decrease in level of consciousness, or persistent comatose state had an 
electroencephalogram examination (EEG) to look for evidence of subclinical seizure.  
EEG results were read as either normal or abnormal, with abnormal results further 
classified as status epilepticus, seizure activity, or seizure tendency.  Only patients who 
warranted and received an EEG were included in the analysis.5 
 A total of fifteen patients in the LEV cohort (47%) and twelve patients in the PHT 
group (29%) were included in the statistical analysis.  One patient in the LEV group had 
seizure activity recorded (6.667%), no seizure activity was recorded in the PHT group.  
This difference was not statistically significant (P = 0.556).  There was an increase in 
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seizure tendency on EEG in the LEV group (46.667%) compared to none in the PHT 
group (P = 0.007).  Adverse drug reactions were not reported. 5  
Szaflarski et al 
 Szaflarski et al4 conducted a prospective, randomized trial with the goal of 
comparing the safety and efficacy of PHT and LEV for seizure prophylaxis.  The study 
included 52 patients with either sTBI or subarachnoid hemorrhage (SAH), with 89% 
having sTBI.  This was a change from the original intent, which was to have 52 patients 
in each group.  Patients were considered to have sTBI if their GCS score was 3-8, or if 
the GCS motor score was five or less and the head CT scan showed intracranial 
pathology.  Patients were analyzed together, and data was unavailable for either the sTBI 
or SAH group independently.  Patients were randomized to receive either LEV (n = 34) 
or PHT (n = 18) for seven days.  All patients were placed on continuous EEG monitoring 
for 72 hours or until they were able to follow commands, whichever came first.  
Szaflarski et al4 cite research indicating that 93% of seizures in this setting occur within 
two days of admission to the ICU as the reason for ceasing EEG monitoring at 72 hours.4 
 The study pharmacist made dosage adjustments in both groups.  Patients receiving 
PHT had their dose adjusted to maintain serum levels of 10-20 mcg/dl.  Patients in both 
groups could also have their dose increased to the maximum recommended dose if 
seizure occurred.  The study methodology provided for the addition of LEV to patients in 
the PHT group, and PHT to patients in the LEV group, as well as the addition of other 
anti-epileptic drugs if seizures were not suppressed at maximum dose of monotherapy, 
but there is no indication of whether or not this was necessary.4 
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 Four out of 18 (22.2%) of patients in the PHT and 14 out of 34 (41.1%) of 
patients in the LEV group expired within six months of injury (P = 0.227).  Cause of 
death was evaluated for each patient and classified as either being due to the injury itself, 
withdrawal of care within thirty days of injury, or withdrawal of care beyond thirty days.  
There was no significant difference between the LEV and PHT groups for each 
classification of death.4 
 No significant difference was found in the rate of seizure between the PHT group 
(3/18, 11%) and the LEV group (5/34, 15%).  All seizures that were recorded were noted 
to be non-convulsive in nature.  The number of seizures that were subclinical versus 
those that were clinically evident was not reported.  The incidence of gastrointestinal 
problems was higher in the PHT group than in the LEV group (22.2% vs. 2.9%, P = 
0.043), though the type, severity, and duration were not reported.  The incidence of 
worsening neurological status was also higher in the PHT group than the LEV group 
(50% vs. 17.6%, P = 0.024).  The definition of worsening neurological status was not 
reported. 4   
Patients who survived at least six months who had been treated with LEV were 
reported to have better long term outcomes than those treated with PHT.  Surviving 
patients treated with LEV had higher Glasgow Outcome Scale-Extended (GOSE) scores 
at six months (P = 0.016), but not at discharge or three months.  After adjusting for initial 
GCS, GOSE was not significantly different at discharge or three months, but at six 
months patients in the LEV group were 1.5 points higher (95%CI 0.1-3.9, P = 0.039) 
than those in the PHT group.  Disability Rating Scale (DRS) was lower at three and six 
months (P = 0.006 and P = 0.037, respectively), but not at discharge.  After adjusting for 
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initial GCS, patients treated with LEV scored 5.2 points lower (95%CI 0.2-10.3, P = 
0.042) on the DRS than those patients treated with PHT at three months, but not at 
discharge or six months.  All other outcomes showed no statistical difference.4 
DISCUSSION 
An exhaustive literature search found only two articles that compare levetiracetam 
(LEV) and phenytoin (PHT) for seizure prophylaxis in the setting of severe traumatic 
brain injury (sTBI), and neither was able to demonstrate a reduction in seizure frequency 
when using LEV.  Jones et al5 reported an increase frequency of abnormal and seizure 
tendency EEG with LEV when compared to PHT, but they did not see a difference in 
actual seizure activity.  They did not address whether or not seizure tendency on EEG, 
without actual seizure activity, leads to harm. 
 Szaflarski et al4 reported an increase in gastrointestinal side effects and increased 
frequency of worsening neurologic status with the use of PHT compared to LEV, but 
critical information is missing.  In particular, the magnitude and duration of the 
gastrointestinal side effects was not reported.  Clinically, there is a big difference 
between mild GI upset and bowel obstruction or pancreatitis, and side effects that would 
make a drug contraindicated if they are persistent might be tolerable if they resolve 
within minutes or hours.  The same information is missing for the worsening of 
neurologic status.  While a decrease in neurologic status is certainly concerning, it may 
be tolerable if it is brief and transient.  
 Szaflarski et al4 report an improvement in long term outcome with the use of 
LEV, though the data to support this are tenuous.  While surviving patients treated with 
LEV have an improvement in their Glasgow Outcome Score-Extended (GOSE) at six 
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months, and Disability Rating Score (DRS) at three and six months, the results are much 
less dramatic after controlling for initial Glasgow Coma Scale (GCS).  Controlling for 
GCS at admission does show an increase in GOSE at 6 months only, and a decrease in 
DRS at six months only, for patients treated with LEV compared to PHT, but the 95% 
confidence intervals (0.1 - 3.0 and 0.2 - 10.3, respectively) suggest that the magnitude of 
effect may be very modest.  These results only apply to surviving patients in each group, 
ignoring death, which is clearly a negative long term outcome.  Death is specifically 
measured by the GOSE, and excluding part of the scale calls into question the validity of 
the reported results. 
 Both Jones et al5 and Szaflarski et al4 used GCS as the determinant of whether or 
not a traumatic brain injury (TBI) qualified as severe.  While a GCS score of less than or 
equal to eight is commonly accepted as severe, this has not been widely applied to seizure 
research.  In developing their practice parameter recommending the use of PHT for 
seizure prophylaxis in the setting of sTBI, the American Academy of Neurology did not 
attempt to define “severe,” relying instead on the definitions used in the individual 
articles that they reviewed.  GCS was not listed as a criterion used by any of the 
contributing articles, with the authors instead using presence of intracranial hematoma, 
loss of consciousness or amnesia for more than 12 or 24 hours, depressed skull fracture, 
and/or presence of brain contusion. 2 This lack of a validated, agreed upon definition for 
severe led Debenham et al3 to retrospectively examine what led physicians at their 
institution to prescribe seizure prophylaxis, and they found that the only two factors that 
significantly correlated with the use of prophylaxis were Marshall CT grade of four or 
more, and the presence of any positive findings on head CT.  This lack of a universal 
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definition of “severe,” and the reliance on GCS alone by Jones et al5 and Szaflarski et al4, 
may limit the applicability of their findings to centers that use other criteria in defining 
which patients qualify as “severe.” 
 The power of both the Jones et al and Szaflarski et al studies4,5 were limited by a 
small sample size.  The small initial n, 73 for the Jones et al5 study and 52 for the 
Szaflarski et al4 study, were further reduced by restricting the groups that were analyzed. 
Jones limited analysis to patients who warranted EEG, which reduced the n to 27.  While 
it was necessary for Szaflarski et al4 to limit long term analysis to surviving patients, this 
reduced the n to 34.  This lack of power makes it difficult to apply the already modest 
results to a larger population.  Debenham et al3 in their retrospective analysis found 653 
patients who were prescribed seizure prophylaxis after sTBI over a two year period at 
their institution alone.  This suggests that, at some centers at least, there is a sufficient 
pool of patients to allow for more powerful research. 
 Given the lack of power, and modest differences between the LEV and PHT 
groups, the cost of using either medication becomes an important consideration.  Cotton 
et al6 performed a cost analysis of PHT vs. LEV, and found that a seven day course of 
PHT, including the associated laboratory costs, was $37.50.  This is far less than the $480 
cost of seven days of LEV. 
 The flaws in the methodology of both the Jones et al and Szaflarski et al studies,4,5 
in particular the small sample size, dramatically decreased the confidence in the results of 
the studies.  This increases the possibility of bias being introduced.  The risk of bias was 
further exacerbated by the selective way in which the results of the Szaflarski et al4 study 
were reported, in particular ignoring death as a measurable outcome on the GOSE and 
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reporting results after controlling for initial GCS for only some outcomes.  Finally, the 
Szaflarski et al4 study was funded by the company which manufactures LEV, which also 
increases the risk of bias. 
CONCLUSION 
The use of phenytoin (PHT) for seizure prophylaxis for seven days in the setting 
of severe traumatic brain injury (sTBI) is the current standard of care.  This systematic 
review examined the available literature to determine if there is sufficient evidence to 
recommend the use of levetiracetam (LEV) in lieu of PHT for seizure prophylaxis, given 
the known side effect profile and drug interactions associated with PHT.  This review has 
found that there is a paucity of evidence comparing LEV and PHT in the setting of sTBI. 
The evidence that is available does not show a difference in the rate of seizure, or a 
substantial difference in the rate of side effects or long term outcomes when comparing 
LEV and PHT.  Ultimately, there is insufficient evidence to recommend a change in 
standard practice, and at this time patients with sTBI should continue to receive PHT as 
seizure prophylaxis for the first seven days post injury. 
 There are legitimate concerns regarding the side effects and drug interactions 
associated with the use of PHT.  There is evidence that a sufficient patient population 
exists to conduct a randomized controlled trial comparing PHT and LEV in the setting of 
sTBI in a fashion that will allow the results to have sufficient power to allow broad 
applicability.  Further high quality research is needed to focus on the efficacy of these 
two medications in preventing seizures, differences in long term outcomes, and the 
frequency and severity of side effects and drug interactions. 
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Table I. Characteristics of Reviewed Studies 
 
Quality Assessment  
Design Limitations Inconsistency Indirectness  Imprecision Other 
considerations Quality 
Jones et al5 
Mixed 
retrospective/prospective 
Downgraded 
due to 
limitations 
* 
No 
inconsistancy 
  
No 
Indirectness Not Reported None 
Very 
Low 
⊕ΟΟΟ 
Szaflarski et al4 
Randomized controlled 
trial 
Downgraded 
due to 
limitations 
* 
No 
Inconsistancy 
  
No 
Indirectness 
Downgraded, 
Inconsitently 
Reported** 
Drug 
Company 
(LEV) 
Funded Study 
Very 
Low      
⊕ΟΟΟ 
*       Small sample size 
   Only patients who experienced seizure were included in analysis 
   Few studies available for comparison 
   Use of additional AEDs allowed including LEV + PHT, not reported if this occurred 
   Pimary outcomes poorly defined 
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Table II. Summary of Findings 
 
Summary of Findings 
Jones et al5 
  
Levetiracetam 
n (%) 
Phenytoin 
n (%) P value 
Included in analysis 15/32 (49.6) 12/41 (29.3) Not reported 
Any abnormal EEG 8/15 (53.3) 0/12 0.003 
Seizure tendency EEG 7/15 (46.66) 0/12 0.007 
Seizure activity EEG 1/15 (6.67) 0/12 0.556 
Suspicion of clinical seizure activity 2/15 (13.3) 3/12 (25) Not reported 
Szaflarski et al4 
Early Seizure 5/34 (14.7) 3/18 (16.6) 1 
Seizure at 6 months 1/20 (0.05) 0/14 1 
Mortality 14/34 (41.2) 4/18 (22.2) 0.227 
Gastrointestinal (all pts) 1/34 (2.9) 4/18 (22.2) 0.043 
Gastrointestinal (surviving pts) 1/20 (5) 3/14 (21.4) 0.283 
Woresening neuro status (all pts) 6/34 (17.6) 9/18 (50.0) 0.024 
Worsening neuro status (surviving pts) 4/20 (20.0) 6/14 (42.9) 0.012 
 
 
